InvestorsHub Logo
icon url

Mortimerduke

12/27/20 6:27 PM

#342818 RE: aperture007 #342814

Bless you Aperture007. You have earned the success you will be enjoying in 2021
icon url

ATLnsider

12/27/20 8:08 PM

#342838 RE: aperture007 #342814

Great job aperture007! Thank you!
icon url

CaptainObvious

12/27/20 8:48 PM

#342844 RE: aperture007 #342814

Excellent
icon url

extrooper

12/27/20 8:54 PM

#342845 RE: aperture007 #342814

great job, thanks for taking the time to construct
icon url

Doc logic

12/27/20 10:49 PM

#342861 RE: aperture007 #342814

aperture007,

Great look at the process. The percentage of solid tumors treatable by this platform will be above your conservative assumption by a significant amount but you walked folks through this process very well. Also quite a few patients from listed and non listed countries will be treated through medical tourism if not available regionally. There are a fe other tweaks too but you and abeta have done yourselves proud with your work in this area. Blessings and best wishes.
icon url

Poor Man -

12/27/20 11:53 PM

#342868 RE: aperture007 #342814

Nice job.

Now, I’m sitting in the audience at the Ihub Biotect Conference, and I’ve raised my hand to ask a few questions:

The young assistant hands me the microphone, while I place my noodle snack on my chair.

Ahem, so...

1) Why isn’t the valuation for L at least the same as for NVCR at year 1 - why the discrepancy;

2) Why isn’t the valuation for L and D separated out;

3) Doesn’t approval in Germany apply to all EU countries - so shouldn’t the rollouts happen about the same time for all countries;

4) What is the assumption for how long various indications for D can go through the approval process from each of the RAs?

At least for L, I agree with your range of between $15 and $30 billion, it makes sense. D is much more difficult to value, and a discounted cash flow approach might be a better methodology, given how forward looking for all the assumptions. Probably better off capturing risk rather than just assuming a multiple of revenue.

Good job on the presentation!
icon url

danielboog2

12/28/20 12:29 AM

#342870 RE: aperture007 #342814

Thanks aperture....Focused and Illuminating.
icon url

X Master

12/28/20 12:59 AM

#342873 RE: aperture007 #342814

I’m sure China will figure into the mix within 5 years.
icon url

sentiment_stocks

12/28/20 2:14 AM

#342877 RE: aperture007 #342814

Thank you aperture 007! Very logical helpful presentation!

Five stars!! :)
icon url

eagle8

12/28/20 3:14 AM

#342883 RE: aperture007 #342814


Thank you aperture007 for your work and sharing with us.

GLTU
icon url

flipper44

12/28/20 9:10 AM

#342912 RE: aperture007 #342814

Thanks Aperture. Much appreciated. I’ll bookmark this so I can go back to it from time to time.
icon url

BigAl2020

12/28/20 9:14 AM

#342916 RE: aperture007 #342814

Nice work... thanks for sharing.
icon url

abeta

12/28/20 10:56 AM

#342965 RE: aperture007 #342814

Hi Aperture007

In a nutshell - Your presentation is STUNNING -
in its explanation of the future valuation of the
DCVax platform.

I really hope -- that somehow -- your presentation finds its
way to Linda Powers for use by her at "" Investor Conferences ""

regards





icon url

jimmy667

12/11/22 6:07 AM

#547288 RE: aperture007 #342814

Aperture007 we my be approaching the a hockey stick part of the Market Cap appreciation curve you predicted almost 2 years ago. Remember it does not take RA approval or partnership/BO to do this many stocks like this flash over in just a few months on market realization of potential.